Related references
Note: Only part of the references are listed.Profiling of lymphoma from formalin-fixed paraffin-embedded tissue
Ryan S. Robetorye et al.
SEMINARS IN HEMATOLOGY (2019)
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma
Grzegorz S. wakowski et al.
BLOOD CANCER JOURNAL (2019)
nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin
Ali G. Saad et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2019)
Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's population-based Haematological Malignancy Research Network
Daniel Painter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma
Xin-Yu Zhang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma
A. Dodero et al.
LEUKEMIA (2019)
Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia
Kean-Chang Phang et al.
JOURNAL OF CLINICAL PATHOLOGY (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms
Hee Sang Hwang et al.
ANNALS OF HEMATOLOGY (2018)
Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Charlott Morth et al.
ANNALS OF HEMATOLOGY (2018)
Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts
Grace Gifford et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Core needle biopsies for the diagnosis of diffuse large B-cell lymphoma - a great concern for research
Maysaa Abdulla et al.
ACTA ONCOLOGICA (2017)
Clinical Impact of the Cell-of-Origin Classification and the MYC/BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group
Annette M. Staiger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
Nara Yoon et al.
ONCOTARGET (2017)
Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact
Daisuke Ennishi et al.
BLOOD (2017)
High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma
Allison Rosenthal et al.
BLOOD REVIEWS (2017)
Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status
Samantha Kendrick et al.
LEUKEMIA & LYMPHOMA (2016)
Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles
Shuangtao Zhao et al.
CANCER MEDICINE (2016)
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
Christiane Copie-Bergman et al.
BLOOD (2015)
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis
Christina Howlett et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
David W. Scott et al.
BLOOD (2014)
Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems
Hee Sang Hwang et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2014)
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
Shimin Hu et al.
BLOOD (2013)
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles
David Cunningham et al.
LANCET (2013)
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Tina Marie Green et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
Nathalie A. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
C. Visco et al.
LEUKEMIA (2012)
Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy
William W. L. Choi et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP
Heidi Nyman et al.
MODERN PATHOLOGY (2009)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
